| Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers YA Guo, MM Chang, W Huang, WF Ooi, M Xing, P Tan, AJ Skanderup Nature communications 9 (1), 1520, 2018 | 148 | 2018 |
| Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer I Joanito, P Wirapati, N Zhao, Z Nawaz, G Yeo, F Lee, CLP Eng, ... Nature genetics 54 (7), 963-975, 2022 | 130 | 2022 |
| Developmental plasticity is bound by pluripotency and the Fgf and Wnt signaling pathways SA Morris, Y Guo, M Zernicka-Goetz Cell reports 2 (4), 756-765, 2012 | 115 | 2012 |
| Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma D Kerdidani, P Chouvardas, AR Arjo, I Giopanou, G Ntaliarda, YA Guo, ... Nature communications 10 (1), 1405, 2019 | 70 | 2019 |
| Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden G Zhu, YA Guo, D Ho, P Poon, ZW Poh, PM Wong, A Gan, MM Chang, ... Nature communications 12 (1), 2229, 2021 | 54 | 2021 |
| Dissecting disease inheritance modes in a three-dimensional protein network challenges the “guilt-by-association” principle Y Guo, X Wei, J Das, A Grimson, SM Lipkin, AG Clark, H Yu The American Journal of Human Genetics 93 (1), 78-89, 2013 | 50 | 2013 |
| Pan-Cancer Analysis of Ligand–Receptor Cross-talk in the Tumor Microenvironment U Ghoshdastider, N Rohatgi, M Mojtabavi Naeini, P Baruah, E Revkov, ... Cancer research 81 (7), 1802-1812, 2021 | 48 | 2021 |
| Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma WF Ooi, AM Nargund, KJ Lim, S Zhang, M Xing, A Mandoli, JQ Lim, ... Gut 69 (6), 1039-1052, 2020 | 46 | 2020 |
| Heritability and inter-population differences in lipid profiles of Drosophila melanogaster CJF Scheitz, Y Guo, AM Early, LG Harshman, AG Clark PLoS One 8 (8), e72726, 2013 | 43 | 2013 |
| Whole-genome noncoding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations S Hu, M Qian, H Zhang, Y Guo, J Yang, X Zhao, H He, J Lu, J Pan, ... Blood, The Journal of the American Society of Hematology 129 (24), 3264-3268, 2017 | 38 | 2017 |
| Exploring mechanisms of human disease through structurally resolved protein interactome networks J Das, R Fragoza, HR Lee, NA Cordero, Y Guo, MJ Meyer, TV Vo, X Wang, ... Molecular BioSystems 10 (1), 9-17, 2014 | 29 | 2014 |
| Integrated network analysis reveals distinct regulatory roles of transcription factors and microRNAs Y Guo, K Alexander, AG Clark, A Grimson, H Yu RNA 22 (11), 1663-1672, 2016 | 27 | 2016 |
| Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition R Sundar, KK Huang, V Kumar, K Ramnarayanan, D Demircioglu, Z Her, ... Gut 71 (7), 1277-1288, 2022 | 25 | 2022 |
| SMuRF: portable and accurate ensemble prediction of somatic mutations W Huang, YA Guo, K Muthukumar, P Baruah, MM Chang, ... Bioinformatics 35 (17), 3157-3159, 2019 | 23 | 2019 |
| Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer M Xing, WF Ooi, J Tan, A Qamra, PH Lee, Z Li, C Xu, N Padmanabhan, ... The Journal of Clinical Investigation 130 (6), 3005-3020, 2020 | 15 | 2020 |
| Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities SWT Ho, T Sheng, M Xing, WF Ooi, C Xu, R Sundar, KK Huang, Z Li, ... Gut 72 (2), 226-241, 2023 | 13 | 2023 |
| MutSpot: detection of non-coding mutation hotspots in cancer genomes YA Guo, MM Chang, AJ Skanderup NPJ genomic medicine 5 (1), 26, 2020 | 13 | 2020 |
| Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. Nat Commun. 2019 D Kerdidani, P Chouvardas, AR Arjo, I Giopanou, G Ntaliarda, YA Guo | 11 | |
| Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer T Sheng, SWT Ho, WF Ooi, C Xu, M Xing, N Padmanabhan, KK Huang, ... Genome Medicine 13 (1), 1-25, 2021 | 8 | 2021 |
| A randomized phase 2 trial of nivolumab versus nivolumab-ipilimumab combination in EGFR-mutant NSCLC GGY Lai, JC Yeo, A Jain, S Zhou, M Pang, JJS Alvarez, NL Sim, AC Tan, ... JTO Clinical and Research Reports 3 (12), 100416, 2022 | 7 | 2022 |
Jishnu DasAssistant Professor, University of Pittsburgh School of MedicineDirección de correo verificada de pitt.edu
